We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

40 hedge funds and large institutions have $121M invested in Adaptimmune Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.02% more ownership

Funds ownership: 0% → 7.02% (+7%)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

13% less funds holding

Funds holding: 46 → 40 (-6)

45% less capital invested

Capital invested by funds: $219M → $121M (-$98.5M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
40
Holders Change
-6
Holders Change %
-13.04%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
10
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VIA
Vident Investment Advisory
Georgia
+$579K
2
Renaissance Technologies
Renaissance Technologies
New York
+$558K
3
AFM
Anson Funds Management
Texas
+$495K
4
AG
Artal Group
Luxembourg
+$480K
5
AA
ALPS Advisors
Colorado
+$326K

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$3.15M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.99M
3
IHM
Iguana Healthcare Management
New York
-$959K
4
RG
Rathbones Group
United Kingdom
-$622K
5
Capital World Investors
Capital World Investors
California
-$578K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$40M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$28.6M – – –
Capital World Investors
3
Capital World Investors
California
$18.1M -$578K -120,514 -3%
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$3.73M – – –
Fidelity International
5
Fidelity International
Bermuda
$3.05M +$5 +1 +0%
O
6
OrbiMed
New York
$2.93M – – –
RSCM
7
Rock Springs Capital Management
Maryland
$2.73M – – –
Millennium Management
8
Millennium Management
New York
$2.72M +$121K +25,170 +4%
QF
9
QVT Financial
New York
$2.66M -$312K -64,975 -9%
TCM
10
Tekla Capital Management
Massachusetts
$2.29M – – –
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$2.16M -$2.99M -623,148 -54%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$2.1M -$265K -55,200 -10%
Renaissance Technologies
13
Renaissance Technologies
New York
$1.8M +$558K +116,400 +35%
AG
14
Artal Group
Luxembourg
$1.22M +$480K +100,000 +50%
A
15
Abingworth
United Kingdom
$1M – – –
RG
16
Rathbones Group
United Kingdom
$812K -$622K -129,600 -39%
VIA
17
Vident Investment Advisory
Georgia
$785K +$579K +120,724 +165%
WMSA
18
Weiss Multi-Strategy Advisers
New York
$446K +$221K +46,000 +72%
AFM
19
Anson Funds Management
Texas
$418K +$495K +103,282 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$407K +$87.4K +18,216 +22%
IHM
21
Iguana Healthcare Management
New York
$405K -$959K -200,000 -67%
BBA
22
Baker Bros. Advisors
New York
$405K – – –
IBT
23
International Biotechnology Trust
United Kingdom
$387K +$463K +96,419 New
AA
24
ALPS Advisors
Colorado
$275K +$326K +68,024 New
State Street
25
State Street
Massachusetts
$266K – – –
1
2 3

ADAP Hedge Fund Activity: Q4 2016 in Review

40 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2016, worth a combined $121M — down 45% from $219M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADAP and 6 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 10 added.

The largest buyer was Vident Investment Advisory, adding an estimated $579K. The largest seller was Putnam Investments, exiting entirely with an estimated $3.15M sold.

  • 40 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2016, down from 46 in Q3 2016.
  • Funds reported $121M of Adaptimmune Therapeutics stock for Q4 2016, down 45% quarter-over-quarter.
  • 6 funds opened new Adaptimmune Therapeutics positions in Q4 2016 and 11 closed out, a net change of -5 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2016 was Vident Investment Advisory, an estimated $579K added.
  • The largest Adaptimmune Therapeutics seller in Q4 2016 was Putnam Investments, an estimated $3.15M sold.

Based on aggregated 13F filings for Q4 2016.